LEXICON PHARMACEUTICALS INC. - COMMON STOCK

Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit

14 Nov 2022 16:03:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference

11 Nov 2022 08:58:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update

09 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics Summit

08 Nov 2022 08:58:00 By Nasdaq GlobeNewswire

New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

06 Nov 2022 17:29:00 By Nasdaq GlobeNewswire

New Analysis of SCORED Trial Demonstrates Sotagliflozin’s Effect on Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

05 Nov 2022 10:35:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022

04 Nov 2022 08:58:00 By Nasdaq GlobeNewswire

New Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular Risk Patients to be Presented at the American Heart Association Scientific Sessions 2022

31 Oct 2022 08:59:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022

24 Oct 2022 08:59:00 By Nasdaq GlobeNewswire

New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Recurrent Heart Failure Events

02 Oct 2022 13:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy

20 Sep 2022 08:59:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Highlights Publications Relating to Sotagliflozin's Differentiated Dual SGLT1 and SGLT2 Mechanism of Action and Potential Implications for Cardiovascular Disease

22 Aug 2022 16:05:00 By Nasdaq GlobeNewswire

Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement

05 Aug 2022 16:59:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

02 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022

29 Jul 2022 08:00:00 By Nasdaq GlobeNewswire

Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement

28 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Lexicon Announces Proposed Public Offering Of Common Stock

27 Jul 2022 16:01:00 By Nasdaq GlobeNewswire

Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure

27 Jul 2022 07:59:00 By Nasdaq GlobeNewswire

Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy

29 Jun 2022 16:01:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the Jefferies 2022 Healthcare Conference

01 Jun 2022 08:00:02 By Nasdaq GlobeNewswire